"Gelre ziekenhuizen, ontstaan vanuit een fusie in 1999, kent een relatief korte historie. We teren echter op een rijk en divers verleden. Inmiddels zijn we een begrip waar het gaat over het verlenen van de juiste medisch specialistische zorg. Met meer dan 3.600 betrokken medewerkers, van medisch specialist tot vrijwilliger, werken we elke dag aan een betere gezondheid voor de 350.000 mensen in ons verzorgingsgebied. Op die manier zijn we figuurlijk én letterlijk (in) het hart van de zorg in onze regio. Daarnaast vervullen we vanuit onze specifieke kennis en kunde op een aantal medische gebieden een bovenregionale functie."

During the past decade, Gelre Ziekenhuizen conducted 80 clinical trials. In the 10-year time frame, 80 clinical trials started and 18 clinical trials were completed, i.e. on average, 22.5% percent of trials that started reached the finish line to date. In the past 5 years, 33 clinical trials started and 11 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Gelre Ziekenhuizen" #1 sponsor was "Radboud University Medical Center" with 16 trials, followed by "Boehringer Ingelheim" with 11 trials sponsored, "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 7 trials sponsored, "European Organisation for Research and Treatment of Cancer - EORTC" with 6 trials sponsored and "UMC Utrecht" with 6 trials sponsored. Other sponsors include 78 different institutions and companies that sponsored additional 57 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Gelre Ziekenhuizen" #1 collaborator was "ZonMw: The Netherlands Organisation for Health Research and Development" with 16 trials as a collaborator, "Amsterdam UMC, location VUmc" with 6 trials as a collaborator, "Eli Lilly and Company" with 6 trials as a collaborator, "Borstkanker Onderzoek Groep" with 4 trials as a collaborator and "Dutch Cancer Society" with 4 trials as a collaborator. Other collaborators include 141 different institutions and companies that were collaborators in the rest 121 trials.

According to Clinical.Site data, the most researched conditions in "Gelre Ziekenhuizen" are "Heart Failure" (6 trials), "Breast Cancer" (4 trials), "Colorectal Cancer" (4 trials), "Lung Cancer" (4 trials) and "Pulmonary Disease, Chronic Obstructive" (4 trials). Many other conditions were trialed in "Gelre Ziekenhuizen" in a lesser frequency.

Most popular intervention types in "Gelre Ziekenhuizen" are "Drug" (78 trials), "Other" (24 trials), "Procedure" (23 trials), "Radiation" (6 trials) and "Behavioral" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (23 trials), "Empagliflozin" (5 trials), "Filgotinib" (4 trials), "cisplatin" (4 trials) and "Bevacizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Gelre Ziekenhuizen" are 115 trials for "All" genders, 13 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are 46 active trials in "Gelre Ziekenhuizen". 1 are not yet recruiting, 27 are recruiting, 15 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 51 completed trials in Gelre Ziekenhuizen, 1 suspended trials, and 15 terminated clinical trials to date.

Out of the total trials that were conducted in Gelre Ziekenhuizen, 0 "Phase 1" clinical trials were conducted, 24 "Phase 2" clinical trials and 46 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 15 trials, and there were also 23 trials that are defined as “Not Applicable".